Exemplis Discimus 2002, 146(2):11-14

Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Baljos Doriena, Goror Gregorya, Nanku Taurendilb, Giriz Crescenta
a Clinic of Dermatology, Raxus Prime University, Republic of Taanab
b 2nd Clinic of Pharmacology, Teaching Hospital of Felucia, Cato Neimoidia Republic

Fusce sem dolor, suscipit quis, commodo ac, consectetuer eget, ligula. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nullam quam ante, viverra eu, cursus et, bibendum in, tortor.. Donec sit amet velit vitae arcu pellentesque commodo. Nam nulla lorem, pellentesque ac, sollicitudin id, pellentesque non, mauris. Fusce sit amet orci in lacus tincidunt malesuada. Cras metus ipsum, aliquam sit amet, ultricies non, ultrices eget, eros. Aliquam eu odio auctor ligula eleifend viverra.

Kľúčové slová: Donec augue, Phasellus metus, Aliquam laoreet, Duis mauris, Suspendisse potenti

Vložený: September 10, 2002; Uverejnené: December 1, 2002 

Zobraziť celý článok

Referencie

  1. Kumar R, Thompson EB (1999) The structure of the nuclear hormone receptors. Steroids 64, 310-319. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  2. Kliewer SA, Lehmann JM, Wilson TM (1999) Orphan nuclear receptors: shifting endocrinology into reverse. Science 284, 757-760. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  3. Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM, Thaller C (1992) 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 68, 397-406. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  4. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzales FJ (2000) Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102, 731-744. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  5. Isseman I, Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  6. Corton JC, Anderson SP, Stauber A (2000) Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu. Rev. Pharmacol. Toxicol. 40, 491-518. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  7. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR - , - , and -  in the adult rat. Endocrinology 137, 354-366.
  8. Mansen A, Guardiola-Diaz H, Rafter J, Branting C, Gustafsson, JA (1996) Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem. Biophys. Res. Commun. 222, 844-851. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  9. Torra IP, Chinetti G, Duval C, Fruchart JC, Staels B (2001) Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr. Opin. Lipidol. 12, 245-254. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  10. Peters JM, Rusyn I, Rose ML, Gonzales FJ, Thurman RG (2000) Peroxisome proliferator activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. Carcinogenesis 21, 823-826. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  11. Miller RT, Anderson SP, Corton JC, Cattley RC (2000) Apoptosis, mitosis and cyclophilin-40 expression in regressing peroxisome proliferator-induced adenomas. Carcinogenesis 21, 647-652. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  12. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK (2001) Effects of PPAR ligands on atherosclerosis. Quiagen News 1, 14-16.
  13. Kersten S, Desvergne B, Wahli W (2000) Roles of PPARs in health and disease. Nature 405, 421-424. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  14. Everett L, Galli A, Crabb D (2000) The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease. Liver 20, 191-199. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  15. Murphy GJ, Holder JC (2000) PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol. Sci. 21, 469-474. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  16. Ashby J, Brady A, Elcombe CR, Elliott BM, Ishmael J, Odum J, Tugwood JD, Kettle S, Purchase IF (1994) Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum. Exp. Toxicol. 13, Suppl. 2: S1-117.
  17. Moore KJ, Fitzgerald ML, Freeman MW (2001) Peroxisome proliferator-activated receptors in macrophage biology: friend or foe? Curr. Opin. Lipidol. 12, 519-527. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  18. Plutzky J (2001) Peroxisome proliferator-activated receptors in endothelial cell biology. Curr. Opin. Lipidol. 12, 511-518. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  19. Wakino S, Kintscher U, Liu Z, Kim S, Yin F, Ohba M, Kuroki T, Schonthal AH, Hsueh WA, Law RE (2001) PPAR gamma ligands inhibit mitogenic induction of p21Cip by modulating the PKC delta pathway in vascular smooth muscle cells. J. Biol. Chem. 276, 47650-47657. Prejsť k pôvodnému zdroju...
  20. Chinetti G, Fruchart JC, Staels B (2001) Peroxisome proliferatoractivated receptors (PPARs): nuclear receptors with functions in the vascular wall. Z. Kardiol. 90, Suppl. 3, 125-132.
  21. Gale EAM (2001) Lessons from the glitazones: a story of drug development. Lancet 357, 1870-1875. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  22. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, Eng C (1999) Loss-offunction mutation in PPAR gamma associated with human colon cancer. Mol. Cell 3, 799-804. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  23. Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee Ch (2001) Tumor suppresor and anti-inflammatory actions of PPAR gamma agonists are mediated via upregulation of PTEN. Curr. Biol. 11, 764-768. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  24. Samid D, Wells M, Greene ME, Shen W, Palmer CNA, Thibault, A. (2000) Peroxisome proliferator-activated receptor gamma as a novel target in cancer therapy: binding and activation by an aromatic fatty acid with clinical antitumor activity. Clin. Cancer Res. 6, 933-941. Prejsť na PubMed...
  25. Brown PH, Lippman SM (2000) Chemoprevention of breast cancer. Breast Cancer Res. Treat. 62, 1-17. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  26. Roberts-Thompson SJ (2000) Peroxisome proliferator-activated receptors in tumorigenesis: targets of tumour promotion and treatment. Immunol. Cell Biol. 78, 436-441. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  27. Lippman SM, Lotan R (2000) Advances in the development of retinoids as chemopreventive agents. J. Nutr. 130, 479S-482S.
  28. Demetri GD, Fletcher CDM, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, Singer S (1999) Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc. Natl. Acad. Sci. USA 96, 3950-3956. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  29. Ferrandina G, Melichar B, Loercher A, Verschraegen CF, Kudelka AP, Edwards CL, Scambia G, Kavanagh JJ, Abbruzzese JL, Freedman LS (1997) Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro. Cancer Res. 57, 4309-4315. Prejsť na PubMed...
  30. Rubin GL, Zhao Y, Kalus AM, Simpson ER. (2000) Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res. 60, 1604-1608. Prejsť na PubMed...
  31. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM (1998) Terminal differentiation of human breast cancer through PPAR gamma. Mol. Cell 1, 465-470. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  32. Jiang WG, Redfern A, Bryce RP, Mansel RE (2000) Peroxisome proliferator activated receptor-gamma (PPAR-gamma) mediates the action of gamma linoleic acid in breast cancer cells. Prostaglandins Leukot. Essent. Fatty Acids 62, 119-127. Prejsť k pôvodnému zdroju...
  33. Thoennes SR, Tate PL, Price TM, Kligore MW (2000) Differential transcriptional activation of peroxisome proliferator-activated receptor gamma by omega-3 and omega-6 fatty acids in MCF-7 cells. Mol. Cell Endocrinol. 160, 67-73. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  34. Collet GP, Betts AM, Johnson MI, Pulimood AB, Cook S, Neal DE, Robson CN (2000) Peroxisome proliferator-activated receptor alpha is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma. Clin. Cancer Res. 6, 3241-3248. Prejsť na PubMed...
  35. Butler R, Mitchell SH, Tindall DJ, Young CY (2000) Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2. Cell Growth Differ. 11, 49-61. Prejsť na PubMed...
  36. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP (1998) Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 58, 3344-3352. Prejsť na PubMed...
  37. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD (1999) Expression of peroxisome proliferator-activated receptor gamma (PPAR gamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1, 330-339. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  38. Padilla J, Kaur K, Harris SG, Phipps RP (2000) PPAR-gammamediated regulation of normal and malignant B lineage cells. Ann. N. Y. Acad. Sci. 905, 97-109. Prejsť k pôvodnému zdroju...
  39. Hirase N, Yanase T, Mu Y, Muta K, Umemura T, Takayanagi R, Nawata H (2000) Thiazolidinedione suppresses the expression of erythroid phenotype in erythroleukemia cell line K562. Leuk. Res. 24, 393-400. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  40. Chang TH, Szabo E (2000) Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res. 60, 1129-1138. Prejsť na PubMed...
  41. Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, Okuyama T, Rumi MA, Fukuda R, Nagasue N, Kinoshita Y (2000) Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br. J. Cancer 83, 1394-1400. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  42. Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, DuBois RN (2000) Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc. Natl. Acad. Sci. USA 97, 13275-13280.
  43. Nwankwo JO, Robbins ME (2001) Peroxisome proliferator-activated receptor-gamma expression in human malignant and normal brain, breast and prostate-derived cells. Prostaglandins Leukot. Essent. Fatty Acids 64, 241-245. Prejsť k pôvodnému zdroju...
  44. Chattopadhyay N, Singh DP, Heese O, Godbole MM, Sinohara T, Black PM, Brown EM (2000) Expression of peroxisome proliferator- activated receptors (PPARS) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis. J. Neurosci. Res. 61, 67-74. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  45. Heneka MT, Feinstein DL, Galea E, Gleichmann M, Wullner U, Klockgether T (1999) Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokineinduced apoptotic cell death by inhibition of inducible nitric oxide synthase. J. Neuroimmunol. 100, 156-168. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  46. Heneka MT, Klockgether T, Feinstein DL (2000) Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J. Neurosci. 20, 6862-6867. Prejsť na PubMed...
  47. Zhou XP, Smith WM, Gimm O, Mueller E, Gao X, Sarraf P, Prior TW, Plass C, von Deimling A, Black PM, Yates AJ, Eng C (2000) Over-representation of PPAR gamma sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population. J. Med. Genet. 37, 410-414. Prejsť k pôvodnému zdroju... Prejsť na PubMed...

Späť na obsah